Association of Corticosteroids with Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab

Félix Lefort; Cécile Dalban; Marine Gross-Goupil; Brigitte Laguerre; Sylvie Chabaud; Bernard Escudier; Laurence Albiges

doi:10.1001/jamaoncol.2023.2296

Association of Corticosteroids with Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab

Félix Lefort, Cécile Dalban, Marine Gross-Goupil, Brigitte Laguerre, Sylvie Chabaud, Bernard Escudier, Laurence Albiges

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

2 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	1295-1298
Nombre de pages	4
journal	JAMA Oncology
Volume	9
Numéro de publication	9
Les DOIs	https://doi.org/10.1001/jamaoncol.2023.2296
état	Publié - 21 sept. 2023

Accès au document

10.1001/jamaoncol.2023.2296

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{09f3f38c3a4a44668fa80e483450dc08,

title = "Association of Corticosteroids with Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab",

author = "F{\'e}lix Lefort and C{\'e}cile Dalban and Marine Gross-Goupil and Brigitte Laguerre and Sylvie Chabaud and Bernard Escudier and Laurence Albiges",

note = "Funding Information: Funding/Support: This work was supported by Unicancer, the French National Cancer Centers Network, which took part in the funding the Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen (NIVOREN) trial for statistical design, data collection, and data analysis, and Bristol Myers Squibb. ",

year = "2023",

month = sep,

day = "21",

doi = "10.1001/jamaoncol.2023.2296",

language = "English",

volume = "9",

pages = "1295--1298",

journal = "JAMA Oncology",

issn = "2374-2437",

number = "9",

}

TY - JOUR

T1 - Association of Corticosteroids with Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab

AU - Lefort, Félix

AU - Dalban, Cécile

AU - Gross-Goupil, Marine

AU - Laguerre, Brigitte

AU - Chabaud, Sylvie

AU - Escudier, Bernard

AU - Albiges, Laurence

N1 - Funding Information: Funding/Support: This work was supported by Unicancer, the French National Cancer Centers Network, which took part in the funding the Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen (NIVOREN) trial for statistical design, data collection, and data analysis, and Bristol Myers Squibb.

PY - 2023/9/21

Y1 - 2023/9/21

UR - http://www.scopus.com/inward/record.url?scp=85172034485&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2023.2296

DO - 10.1001/jamaoncol.2023.2296

M3 - Letter

C2 - 37440214

AN - SCOPUS:85172034485

SN - 2374-2437

VL - 9

SP - 1295

EP - 1298

JO - JAMA Oncology

JF - JAMA Oncology

IS - 9

ER -